Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.

Hoi Shan Wong, Jacob Z Chen, Bilin Chou, Jason S. Halladay, Jane R. Kenny, Hank La, James C. Marsters Jr, Emile Plise, Patrick J. Rudewicz, Kirk Robarge, Young Shin, Susan Wong, Chi Zhang, S. Cyrus Khojasteh
November 1, 2009
Learn More
LinkedIn